1. B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Gay, F; Berdeja, JG; De Stefano, V; Hari, P; Hooper, B; Haltner, A; Kumar, S; Martin, T; Mateos, M-V; Moreau, P; Rosta, E; Samjoo, IA; Usmani, SZ; Weisel, K; Jackson, CC; Olyslager, Y; Schecter, JM; Vogel, M; Garrett, A; Lee, S Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS. (5th April 2022) Authors: van de Donk, NWCJ; Delforge, M; Agha, M; Cohen, AD; Cohen, YC; Hillengass, J; Anguille, S; Kerre, T; Roeloffzen, W; Schecter, JM; De Braganca, KC; Varsos, H; Wang, L; Vogel, M; Zudaire, E; Corsale, C; Akram, M; Geng, D; Nesheiwat, T; Pacaud, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY. (5th April 2022) Authors: Einsele, H; Cohen, AD; Delforge, M; Hillengass, J; Goldschmidt, H; Weisel, K; Raab, M-S; Scheid, C; Schecter, JM; De Braganca, KC; Varsos, H; Yeh, T-M; Wang, L; Vogel, M; Corsale, C; Akram, M; Pacaud, L; Nesheiwat, T; Agha, M; Cohen, YC Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗